Med. praxi. 2024;21(3):155-161

Pharmacotherapy for chronic pain

MUDr. Dana Vondráčková
Ambulance pro léčbu bolesti, Neurochirurgická a neuroonkologická klinika 1. LF UK, subkatedra algeziologie IPVZ, Praha

Chronic pain is a chronic disease that significantly impairs the patient's quality of life. Pharmacotherapy is based on international recommendations (IASP, EFNS) adapted by the Society for the Study of Pain Management (SSLB) for our conditions. The correct pain treatment must be complex. It should combine application of pharmaceuticals, intervention techniques, psychotherapy, rehabilitation, and cooperation with other specialists as well. The article deals with pharmacotherapy. Treatment by drugs includes WHO analgesics (1st grade non-opioid analgesics, NSAIDs, 2nd grade weak opioids, 3rd grade strong opioids), co-analgesics, antidepressants, antiepileptics, and other adjuvant therapies. The main part deals with analgesics, interactions, and side effects are also mentioned. In conclusion, the principle of choosing the complex pharmacotherapy is briefly described. Pharmacotherapy for chronic non-cancer pain (CNCP) is also discussed.

Keywords: chronic pain, pain management, non­‑opioid drugs, NSAIDs, weak opioids, strong opioids.

Published: June 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vondráčková D. Pharmacotherapy for chronic pain. Med. praxi. 2024;21(3):155-161.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kozák J. Bolest a její nová definice. MT, 21. září 2020 https://www.tribune.cz/archiv/bolest­‑a-jeji­‑nova­‑definice/.
    2. Fricová J, Hakl M. Metodické pokyny pro farmakoterapii bolesti. Bolest. 2017;19(Supl. 2):1-28.
    3. Bednařík J, Ambler Z. Klinický standard profarmakoterapii neuropatické bolesti. Cesk Slov Neurol N 2012; 75/108(1): 93-101.
    4. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-1188. Go to original source... Go to PubMed...
    5. Jackson TP, SuttonStabile V, McQueen KAK. The global burden of chronic pain. ASANewsletter. 2014;78(6):24-27. Go to original source...
    6. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Surveyofchronicpain in Europe: prevalence, impact on dailylife, and treatment. Eur J Pain. 2006;10:287-333. Go to original source... Go to PubMed...
    7. Hakl M. Metamizol jako analgetikum první volby. www.prolekare.cz. 21. srpen 2021 https://www.prolekare.cz/tema/analgesie/detail/metamizol­‑jako­‑analgetikum­‑prvni­‑volby­‑kdy­‑pro­‑koho­‑jak­‑a-proc-128047.
    8. Nosková P. Nové fixní kombinace při léčbě bolesti a jejich použití. Med. praxi. 2022;19(2):115-18. https://doi.org/10.36290/med.2022.016. Go to original source...
    9. Halbichová, D. Analgetika v neurologii, jejich specifika a nežádoucí účinky. Neurol. praxi. 2022;23(1):76-83. https://doi.org/10.36290/neu.2021.093. Go to original source...
    10. Slíva, J. Fixní kombinace paracetamol + ibuprofen". Cetalgen, 7. leden 2021. https://cetalgen.cz/fixni­‑kombinace­‑paracetamol­‑ibuprofen/.
    11. Rokyta R. Patofyziologie a mechanismy účinků opioidů. In Kozák J et al. Opioidy. 2. vyd. Maxdorf 2021;71-80.
    12. Shug SA. The typical opioids: buprenorphine, tramadol and tapentadol. Med Today. 2019;20:31-36.
    13. Halačová M, Vrba I. Farmakokinetické lékové interakce a metabolismus opioidů. In Kozák J et al. Opioidy. 2. vyd. Maxdorf 2021;131-147.
    14. Babalonis, S, Walsh SL. Warnings Unheeded: TheRisksof Co­‑PrescribingOpioids and Benzodiazepines. Painclinicalupdates. 2015;23(6):1-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747834/.
    15. Halačová M, Vrba I. Interakce v léčbě opioidů. In Kozák J et al. Opioidy 2. vyd. Maxdorf 2021; 147-151.
    16. Vondráčková D. Obstipace vyvolaná opioidy - naloxegol. Podpůrná léčba. 2021;4:14-18.
    17. Lejčko J, Popov P. Opioidy a závislost. In Kozák J et al. Opioidy 2. vyd. Maxdorf 2021;116-130.
    18. Vondráčková D, Vorlíková H. Konopí v léčbě bolesti. MT, 27. prosinec 2021. https://www.tribune.cz/archiv/konopi­‑v-lecbe­‑bolesti/.
    19. Málek J. Epidemiologie používání opioidů. In: Kozák J et al. Opioidy 2. vyd. Maxdorf 2021;46-54.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.